AER-271

AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke[1].

Product Specifications

CAS Number

[634913-39-6]

Product Name Alternative

(Rac)-RP-55787

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Aquaporin

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/aer-271.html

Concentration

10mM

Purity

96.90

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2OP(O)(O)=O

Molecular Formula

C15H9ClF6NO5P

Molecular Weight

463.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Wallisch JS, et al. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85 (4) :511-517.|[2]Farr GW, et al. Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury. Neuroscience. 2019 Apr 15;404:484-498.